Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Immunomedics, Inc. |
---|---|
Information provided by: | Immunomedics, Inc. |
ClinicalTrials.gov Identifier: | NCT00054834 |
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkins Lymphoma |
Drug: hLL2 (epratuzumab) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Official Title: | A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Disease Characteristics:
Prior/Concurrent Therapy:
Patient Characteristics/Inclusion Criteria:
United States, Pennsylvania | |
Fox Chase Cancer Center | |
Philadelphia, Pennsylvania, United States | |
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States |
Study ID Numbers: | IM-T-hLL2-14 |
Study First Received: | February 11, 2003 |
Last Updated: | January 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00054834 |
Health Authority: | United States: Food and Drug Administration |
Lymphatic Diseases Immunoproliferative Disorders Lymphoma, small cleaved-cell, diffuse Lymphoproliferative Disorders |
Lymphoma, Non-Hodgkin Lymphoma Recurrence |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |